US EditionHarbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
- Harbour BioMed announced a global collaboration with Otsuka Pharmaceutical Co., Ltd. to advance BCMAxCD3 bispecific T-cell engagers for autoimmune diseases.
- Otsuka received an exclusive license to develop HBM7020 globally, except for Greater China.
- Harbour BioMed will receive $47 million in upfront payments and could earn up to $623 million with future milestones.
- Both companies aim to establish a foundation for future partnerships in the T-cell engager area.
Insights by Ground AI
Does this summary seem wrong?
54 Articles
54 Articles
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collaboration with…
Formation Bio’s up to €545M licensing deal with Sanofi; Otsuka, Harbour BioMed team up
Plus, news about Incyte, Carisma Therapeutics, Idorsia, Leap Therapeutics, Enterome, Merck, Forte Biosciences, Enzon and Viskase: Formation Bio licenses JAK/SYK inhibitor to Sanofi: The startup said the deal could be worth ...
Coverage Details
Total News Sources54
Leaning Left5Leaning Right6Center18Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
L 17%
C 62%
R 21%
Factuality
To view factuality data please Upgrade to Premium
